RSLBF
RaySearch Laboratories AB (publ)
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
16.85
▼ 2.00 (10.61%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
18.85
Day high
16.85
Day low
16.85
Volume
100
Market cap
—
P/E (TTM)
—
52W range
16.85 – 28.60
Trailing performance
Returnvs SPY
1W
0.00%
+1.2%
1M
0.00%
-3.3%
3M
-23.45%
-25.8%
6M
-18.04%
-29.9%
YTD
-20.80%
-32.8%
1Y
-38.70%
-58.8%
3Y
+192.25%
+117.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on RSLBF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $1.34B | $1.19B | $1.02B | $843.65M | +12.8% |
| Operating revenue | $1.34B | $1.19B | $1.02B | $843.65M | +12.8% |
| Cost of revenue | $101.90M | $99.50M | $106.58M | $94.99M | +2.4% |
| Gross profit | $1.24B | $1.09B | $915.58M | $748.66M | +13.7% |
| Research & development | $270.40M | $269.40M | $237.74M | $238.77M | +0.4% |
| Selling, general & admin | $650.20M | $576.20M | $558.01M | $481.14M | +12.8% |
| Total operating expense | $912.80M | $841.10M | $793.10M | $718.35M | +8.5% |
| Operating income | $329.60M | $251.40M | $122.48M | $30.31M | +31.1% |
| Net interest income | -$2.40M | $0 | -$4.79M | -$10.37M | — |
| Pre-tax income | $287.80M | $262.90M | $110.09M | $32.38M | +9.5% |
| Tax provision | $60.00M | $59.40M | $28.52M | $8.60M | +1.0% |
| Net income | $227.80M | $203.50M | $81.57M | $23.78M | +11.9% |
| Net income to common | $227.80M | $203.50M | $81.57M | $23.78M | +11.9% |
| Basic EPS | 6.65 | 5.94 | 2.38 | 0.69 | +12.0% |
| Diluted EPS | 6.65 | 5.94 | 2.38 | 0.69 | +12.0% |
| EBIT | $295.60M | $271.90M | $119.78M | $43.85M | +8.7% |
| EBITDA | $586.80M | $571.30M | $405.93M | $340.85M | +2.7% |
| Basic shares | 34.28M | 34.28M | 34.28M | 34.28M | 0.0% |
| Diluted shares | 34.28M | 34.28M | 34.28M | 34.28M | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $407.30M | $462.70M | $343.68M | $160.27M | — | -12.0% |
| Cash & short-term investments | $407.30M | $462.70M | $343.68M | $160.27M | — | -12.0% |
| Accounts receivable | -$9.20M | $254.60M | $240.10M | $250.07M | — | -103.6% |
| Inventory | $22.00M | $10.60M | $9.32M | $14.09M | — | +107.5% |
| Total current assets | $970.70M | $984.70M | $802.45M | $627.92M | — | -1.4% |
| Property, plant & equipment | $447.40M | $526.60M | $590.42M | $649.07M | — | -15.0% |
| Goodwill & intangibles | $558.70M | $548.20M | $530.46M | $518.66M | — | +1.9% |
| Total assets | $1.99B | $2.09B | $1.95B | $1.88B | — | -4.7% |
| Total current liabilities | $569.90M | $703.80M | $675.05M | $637.10M | — | -19.0% |
| Current debt | — | — | — | — | $21.27M | — |
| Total debt | $394.80M | $472.00M | $529.36M | $555.39M | — | -16.4% |
| Total liabilities | $1.01B | $1.21B | $1.22B | $1.22B | — | -17.1% |
| Retained earnings | $982.00M | $856.90M | $721.98M | $640.41M | — | +14.6% |
| Shareholder equity | $985.30M | $876.70M | $735.23M | $657.16M | — | +12.4% |
| Working capital | $400.80M | $280.90M | $127.40M | -$9.18M | — | +42.7% |
| Net tangible assets | $426.60M | $328.50M | $204.78M | $138.49M | — | +29.9% |
| Shares issued | 34.28M | 34.28M | 34.28M | 34.28M | — | 0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $287.80M | $262.90M | $110.09M | $32.38M | +9.5% |
| Depreciation & amortisation | $291.20M | $299.40M | $286.15M | $296.99M | -2.7% |
| Change in working capital | -$141.80M | -$25.30M | $61.39M | $6.00M | -460.5% |
| Operating cash flow | $387.00M | $485.20M | $455.93M | $320.66M | -20.2% |
| Capital expenditure | -$228.10M | -$217.60M | -$209.33M | -$201.38M | -4.8% |
| Investing cash flow | -$228.10M | -$217.50M | -$209.33M | -$201.38M | -4.9% |
| Dividends paid | -$102.80M | -$68.60M | — | — | -49.9% |
| Financing cash flow | -$179.60M | -$159.80M | -$56.35M | -$72.49M | -12.4% |
| Free cash flow | $158.90M | $267.60M | $246.60M | $119.28M | -40.6% |
| End cash position | $407.30M | $462.20M | $343.68M | $160.27M | -11.9% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $290.30M | $375.40M | $332.30M | $304.87M | $331.70M | -22.7% |
| Operating revenue | $290.30M | $375.40M | $332.30M | $304.87M | $331.70M | -22.7% |
| Cost of revenue | $23.50M | $35.20M | $11.80M | $27.90M | $26.50M | -33.2% |
| Gross profit | $266.80M | $339.20M | $320.50M | $276.97M | $305.20M | -21.3% |
| Research & development | $56.80M | $70.10M | $68.20M | $72.96M | $58.80M | -19.0% |
| Selling, general & admin | $156.10M | $167.60M | $164.10M | $161.64M | $156.90M | -6.9% |
| Total operating expense | $199.10M | $247.40M | $231.40M | $240.61M | $230.30M | -19.5% |
| Operating income | $67.70M | $91.80M | $89.10M | $36.36M | $74.90M | -26.3% |
| Net interest income | $400.00K | -$3.20M | -$700.00K | $3.21M | -$3.80M | +112.5% |
| Pre-tax income | $68.00M | $88.20M | $88.50M | $39.57M | $71.00M | -22.9% |
| Tax provision | $14.70M | $20.10M | $16.90M | $8.81M | $14.20M | -26.9% |
| Net income | $53.20M | $68.60M | $71.60M | $30.76M | $56.80M | -22.4% |
| Net income to common | $53.20M | $68.60M | $71.60M | $30.76M | $56.80M | -22.4% |
| Basic EPS | 1.55 | 2.00 | 2.09 | 0.90 | 1.66 | -22.5% |
| Diluted EPS | 1.55 | 2.00 | 2.09 | 0.90 | 1.66 | -22.5% |
| EBIT | $67.70M | $91.80M | $89.10M | $36.36M | $74.80M | -26.3% |
| EBITDA | $67.70M | $91.80M | $89.10M | $36.36M | $74.80M | -26.3% |
| Basic shares | 34.28M | 34.28M | 34.28M | 34.18M | 34.28M | 0.0% |
| Diluted shares | 34.28M | 34.28M | 34.28M | 34.18M | 34.28M | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $439.30M | $407.30M | $322.80M | $402.81M | $503.38M | — | +7.9% |
| Cash & short-term investments | $439.30M | $407.30M | $322.80M | $402.81M | $503.38M | — | +7.9% |
| Accounts receivable | $195.60M | -$9.20M | $208.80M | $194.32M | $189.79M | — | +2,226.1% |
| Inventory | $49.00M | $22.00M | $25.70M | $35.86M | $10.66M | — | +122.7% |
| Total current assets | $1.01B | $970.70M | $911.20M | $936.86M | $986.40M | — | +4.0% |
| Property, plant & equipment | $430.30M | $447.40M | $464.80M | $478.17M | $501.63M | — | -3.8% |
| Goodwill & intangibles | $576.50M | $558.70M | $551.70M | $560.48M | $558.52M | — | +3.2% |
| Total assets | $2.03B | $1.99B | $1.94B | $1.99B | $2.06B | — | +1.8% |
| Total current liabilities | $563.20M | $569.90M | $573.10M | $667.35M | $643.62M | — | -1.2% |
| Total debt | $377.30M | $394.80M | $411.10M | $429.98M | $449.44M | — | -4.4% |
| Total liabilities | $984.90M | $1.01B | $1.02B | $1.14B | $1.14B | — | -2.2% |
| Retained earnings | — | $982.00M | — | — | — | $856.90M | — |
| Shareholder equity | $1.04B | $985.30M | $919.30M | $848.93M | $921.97M | — | +5.8% |
| Working capital | $446.20M | $400.80M | $338.10M | $269.52M | $342.77M | — | +11.3% |
| Net tangible assets | $466.20M | $426.60M | $367.60M | $288.45M | $363.46M | — | +9.3% |
| Shares issued | 34.28M | 34.28M | 34.28M | 34.28M | 34.28M | — | 0.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | $68.00M | $88.70M | $88.50M | $39.57M | $71.00M | -23.3% |
| Change in working capital | -$2.00M | $18.10M | -$160.00M | -$20.58M | $20.70M | -111.0% |
| Operating cash flow | $116.90M | $173.20M | -$11.60M | $70.58M | $146.80M | -32.5% |
| Capital expenditure | -$67.40M | -$62.50M | -$51.00M | -$52.75M | -$61.90M | -7.8% |
| Investing cash flow | -$67.40M | -$62.50M | -$50.90M | -$52.75M | -$61.90M | -7.8% |
| Dividends paid | — | — | — | -$102.85M | — | — |
| Financing cash flow | -$19.40M | -$19.40M | -$19.10M | -$121.77M | -$19.30M | 0.0% |
| Free cash flow | $49.50M | $110.70M | -$62.60M | $17.83M | $84.90M | -55.3% |
| End cash position | $439.30M | $407.30M | $322.80M | $402.81M | $503.40M | +7.9% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
18.85
-10.61% from price
SMA 20
18.85
0.00% from price
SMA 50
20.21
-6.74% from price
SMA 100
21.71
-22.39% from price
SMA 200
23.32
-19.15% from price
EMA 12
18.88
-10.77% from price
EMA 26
19.26
-12.53% from price
EMA 50
20.11
-16.21% from price
RSI (14)
36.6
Neutral
MACD (12,26,9)
-0.38
Hist 0.12
ATR (14)
0.00
—
Realised vol 30D
106.8%
Annualised
Bollinger upper
18.85
20, 2σ
Bollinger lower
18.85
20, 2σ
50 / 200 cross
Death
20.21 vs 23.32
Trend bias
Below 200
-19.15%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.06
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
106.8%
Annualised
Market vol 1Y
12.8%
SPY, annualised
Max drawdown 1Y
-45.2%
Peak to trough
Max drawdown 5Y
-55.1%
Peak to trough
ATR 14
0.00
Average true range
Beta (reported)
—
5Y monthly, from filing
Headlines
RaySearch Laboratories AB (RSLBF) (Q2 2026) Earnings Call Highlights: Order Intake Surges 23% ...
GuruFocus.com · 4d ago
European Undervalued Small Caps With Insider Activity To Watch In June 2026
Simply Wall St. · 71d ago
Marie® by Leo Cancer Care Makes History at Stanford Medicine — World First in Compact Upright Proton Therapy
Business Wire · 76d ago
Top European Growth Companies With High Insider Ownership June 2026
Simply Wall St. · 81d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.